|
|
|
|
|
| Mahesh Satwekar; Abhijeet Satwekar. |
| Acute and chronic progression of injury to the kidney leads to the failure of the renal system and has become an increasingly important cause of morbidity and mortality. Present diagnosis detects the condition only after irreversible loss of 70 percent of kidney function. Current research is focused only on the clinical manifestations after the kidney injuries and not towards the exact cause of the condition. Here we propose a new outlook- that there is an involvement of a pathogen in the pathogenesis of kidney injuries. Basis for our proposal is given by the similarity of the pathogenesis events occurring between a classical example of hepatitis and kidney injuries. Furthermore, literature regarding the role of early kidney injury biomarkers in innate... |
| Tipo: Manuscript |
Palavras-chave: Biotechnology; Immunology; Microbiology. |
| Ano: 2012 |
URL: http://precedings.nature.com/documents/7021/version/1 |
| |
|
|
| Abhijeet Satwekar. |
| Transglutaminase (TGase) catalyzes an acyl transfer reaction between the [gamma]-carboxamide group of glutamine (Gln) and the [epsilon]-amino group of lysine (Lys) residues to form a stable amide bond. The TGase reaction can be used for bioconjugation of an amino-derivative of poly-ethylene glycol (PEG) to protein drugs, leading to PEGylated proteins that display increased bioactivity and stability. The procedure was shown to lead to site-specific bioconjugation of few proteins, thus offering a valid alternative to the chemical methods of PEGylation in current use (1). Moreover, TGase can be used for site-specifically labeling proteins with fluorescent groups at the level of Gln or Lys for diagnostic applications. The TGase attack is not entirely dependent... |
| Tipo: Poster |
Palavras-chave: Biotechnology; Chemistry. |
| Ano: 2011 |
URL: http://precedings.nature.com/documents/6000/version/1 |
| |
|
|
| Abhijeet Satwekar. |
| Commercially available recombinant protein drugs often cause immune reactions in the body which reduces their efficiency. Protein drugs can be PEGylated, (attachment of polyethylene glycol) to overcome this problem. PEGylation increases bioavailability by reduced immune reactions and decreased renal clearance [1]. So far the traditional approaches for PEGylation involve harsh reaction conditions which provide a heterogeneous product (PEG attached randomly to different sites) along with the formation of several byproducts. Due to heterogeneity, the PEGylated protein drug faces challenge for FDA approval. Therefore, there is an immense need to develop an approach which could generate a homogeneous PEGylated protein drug. 
The... |
| Tipo: Poster |
Palavras-chave: Biotechnology; Chemistry; Pharmacology. |
| Ano: 2011 |
URL: http://precedings.nature.com/documents/5671/version/1 |
| |
|
|
|
